AbCellera Biologics's total assets for Q3 2024 were $1.39B, a decrease of -1.39% from the previous quarter. ABCL total liabilities were $314.73M for the fiscal quarter, a 77.49% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.